Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23327

    +

    P2.03-056 - Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 in Slovakian NSCLC Patients - Updated Survival Data (ID 10507)

    09:30 - 16:00  |  Presenting Author(s): Peter Berzinec
    • Abstract
    • Slides

    Background:
    Primary EGFR dual mutations comprising T790M and exon 19 or 21 mutation (SM, sensitizing mutations) are rare in the Caucasian population, and there are only limited data about the treatment results with EGFR-TKIs in this setting. In 2016 we published results of the Slovakian retrospective study, in which six cases of the primary EGFR dual mutations T790M and SM were found among 3883 patients with NSCLC tested for EGFR mutations. Here we present the treatment results with updated PFS and OS data.
    
    Method:
    In this retrospective multicentre study the databases of the molecular/genetic diagnostic centres were searched for patients with primary dual EGFR mutations T790M and SM. Data about treatment results in these patients were obtained from the databases of the participating institutions and patient files. Kaplan-Meier survival analyses were done with MedCalc software, v. 17.5.
    
    Result:
    Patients’ characteristics and the treatment results are in the Table. PS was improved after two months of treatment in patients with initial PS over 1, and remained unchanged in those with PS 1. There were no unexpected AEs. Median PFS was 16 months, 95%CI: 12 - 23 months, median OS: 26 months, 95%CI: 18 - 26+ months. Table: Characteristics of patients with primary dual EGFR mutations T790M and SM (sensitizing mutation), and results of treatment with EGFR-TKIs

    Gender (M/W)	Age (yrs)	Smoking status	PS	NSCLC histology	Stage	T790M + SM	Treatment line/TKI	Response	PFS (mo)	OS (mo)
    W	57	Never	3	AC	IV	Del 19	1st/afatinib	PR	12	28+
    W	64	Never	1	AC	IV	Del 19	2nd/erlotinib	SD	16	18
    W	71	Never	1	AC	IV	Del 19	1st/afatinib	SD	10	17+
    W	72	Ex	2	AC	IV	Del 19	1st/gefitinib	SD	54+	54+
    W	72	Never	1	NOS	IV	Del 19	1st/erlotinib	PR	20	26
    W	75	Never	1	AC	IV	Del 19	1st/afatinib	SD	24	25

    
    
    Conclusion:
    Results in our group of patients with primary dual EGFR mutations T790M and SM treated with first or second generation ERGFR TKIs are comparable with results seen in NSCLC patients with the SM only. The quantitative analysis of these mutations using either the recent tumour tissue or the blood sample is available at present. It might be useful in decision making about the use of the first – second, or the third generation EGFR-TKI, based on the prevailing mutation.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.